Podcast

Speaking of Urology: How to get started with HIFU for prostate cancer

Author(s):

Urology Times staff

In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.

Listen to the rest of this interview:

Part 1: A HIFU expert discusses his treatment criteria

Part 2: What patients undergoing HIFU should expect postoperatively

Related Videos
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Dr Louise Kostos answers a question during a Zoom video interview
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos discusses PSA kinetics in mHSPC
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Related Content
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
April 3rd 2025

CD46-targeting ADC shows encouraging clinical activity in mCPRC

Hannah Clarke
The company plans to initiate the phase 2 monotherapy trial by mid-year.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA updates in urology: March 2025
April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from March 2025.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
NeuroSAFE procedure for RARP leads to improved erectile function
March 27th 2025

NeuroSAFE procedure for RARP leads to improved erectile function

Hannah Clarke
“Our results show that by using NeuroSAFE, nearly twice as many men don’t have to face potentially life-changing loss of erectile function after prostate surgery,” says Professor Greg L. Shaw.
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke
“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
© 2025 MJH Life Sciences

All rights reserved.